DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a note issued to investors on Saturday. The firm set a “hold” rating on the stock.

Several other research analysts have also issued reports on DBVT. JMP Securities reiterated a “market outperform” rating and set a $5.00 price objective on shares of DBV Technologies in a research note on Tuesday, September 24th. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of DBV Technologies in a research report on Thursday, August 1st.

DBV Technologies Stock Performance

Shares of DBVT opened at $0.69 on Friday. The firm has a market cap of $66.14 million, a PE ratio of -0.82 and a beta of 0.68. The firm’s 50 day moving average price is $0.84 and its 200 day moving average price is $1.04. DBV Technologies has a twelve month low of $0.50 and a twelve month high of $2.64.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same period last year, the firm posted ($0.26) EPS. On average, sell-side analysts anticipate that DBV Technologies will post -1.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. raised its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies makes up about 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities & Exchange Commission. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.